The H. pylori Battle Plan: Beyond Triple Therapy

If you have been treated for Helicobacter pylori and it did not work — if you took two weeks of antibiotics, endured the side effects, retested, and were told the infection is still there — you are part of a growing population of patients facing one of the most challenging problems in modern gastroenterology: antibiotic-resistant H. pylori.

You are not alone. Eradication failure rates for standard first-line therapy have climbed steadily over the past decade, and in some Australian populations, failure rates now exceed 30 to 40 percent. But treatment failure is not the end of the story. It is the point at which a smarter, more personalised strategy becomes essential.

Why Standard Triple Therapy Fails

The standard first-line regimen for H. pylori — a proton pump inhibitor with amoxicillin and clarithromycin — was designed in an era when clarithromycin resistance was rare. That era is over. Clarithromycin resistance in Australia now affects a significant minority of H. pylori strains, and prescribing clarithromycin-based therapy without knowing the organism's resistance profile is increasingly a gamble.

Metronidazole resistance is even more prevalent, particularly in patients born overseas or previously treated with metronidazole for other conditions. Dual resistance — to both clarithromycin and metronidazole — renders most standard regimens essentially ineffective.

Other factors compound the problem. Proton pump inhibitor metabolism varies between individuals based on genetic polymorphisms in the CYP2C19 enzyme. Rapid metabolisers break down PPIs quickly, resulting in less effective acid suppression and a less favourable environment for antibiotic activity. Smoking, poor adherence due to side effects, and high bacterial load all contribute to treatment failure.

The Case for Culture-Guided Therapy

After a first treatment failure, the single most valuable diagnostic step is endoscopy with gastric biopsy for culture and antibiotic sensitivity testing. This allows us to identify exactly which antibiotics the H. pylori strain is resistant to and design a salvage regimen with confidence rather than guesswork.

Culture-guided therapy has been shown to significantly improve eradication rates compared to empiric second-line treatment. It transforms H. pylori management from a trial-and-error approach to precision medicine. The endoscopy also provides valuable information about the state of the gastric mucosa — allowing us to assess for atrophic gastritis, intestinal metaplasia, or other changes that may alter the urgency and approach to treatment.

Vonoprazan: The Game Changer

The introduction of vonoprazan has been one of the most significant advances in H. pylori treatment in recent years. Vonoprazan is a potassium-competitive acid blocker that differs fundamentally from traditional proton pump inhibitors. It achieves more rapid, more potent, and more sustained acid suppression, and its efficacy is not affected by CYP2C19 polymorphisms — meaning it works equally well in rapid and poor metabolisers.

This matters enormously for H. pylori eradication because the antibiotics used against H. pylori work best in a less acidic environment. More effective acid suppression translates directly to higher antibiotic efficacy and higher eradication rates.

In our practice, we have incorporated vonoprazan into our salvage regimens with striking results. Our current advanced protocol — vonoprazan combined with rifabutin, amoxicillin, and bismuth — has achieved a 92 percent eradication rate in patients with refractory H. pylori. These are patients who have already failed two or more standard treatment courses and whose organisms are, by definition, the most resistant.

Why This Combination Works

Each component of our salvage regimen serves a specific purpose. Vonoprazan provides superior acid suppression, creating the optimal gastric environment for antibiotic activity. Rifabutin is a critical inclusion because H. pylori resistance to rifabutin remains exceedingly rare worldwide — it is an antibiotic that the organism has not yet learned to evade. Amoxicillin retains excellent activity against most H. pylori strains, as resistance to amoxicillin is uncommon. Bismuth provides an additional antimicrobial effect through a mechanism distinct from conventional antibiotics, and it also has mucosal-protective properties.

The combination attacks H. pylori from multiple angles simultaneously, leaving the organism very few avenues of escape. This multi-pronged approach is essential when dealing with resistant strains.

Gastric Microbiome Transplant: The Horizon

Looking beyond conventional pharmacotherapy, one of the most exciting horizons in H. pylori management is gastric microbiome transplantation. We now know that the stomach, once thought to be essentially sterile, harbours a diverse microbial community. Chronic H. pylori infection disrupts this community, and even after successful eradication, the gastric microbiome may remain altered.

Gastric microbiome transplantation aims to restore the normal gastric microbial ecology after eradication, potentially reducing the risk of reinfection and optimising mucosal healing. This is a genuinely novel frontier that we are actively exploring in our practice.

A Systematic Approach to a Stubborn Infection

The key message for patients with refractory H. pylori is that effective treatment is available — but it requires a systematic, specialist-led approach. Empiric cycling through standard regimens without knowing the organism's resistance profile is unlikely to succeed and risks generating further resistance.

• Confirm the infection with accurate testing (urea breath test or biopsy-based methods)

• Obtain culture and sensitivity data via endoscopy to guide antibiotic selection

• Use vonoprazan-based regimens for superior acid suppression

• Incorporate antibiotics with low resistance rates, such as rifabutin

• Confirm eradication with post-treatment testing at least four weeks after completing therapy

Managing Expectations and Optimising Outcomes

Refractory H. pylori can be a frustrating condition, both for patients and clinicians. The fact that the infection persists after conventional therapy often triggers cycles of repeated empiric treatments, each with their own side effects and risks, but with diminishing confidence that they will work. Our approach is different: we move quickly to specialised diagnostics, obtain concrete resistance data, and design a regimen with confidence rather than hope.

It is also important to address potential adherence and absorption issues. Some patients with severe gastric atrophy or intestinal metaplasia may have significant achlorhydria (lack of stomach acid), which actually impairs the eradication of H. pylori. Vonoprazan is particularly valuable in these patients because it works through a mechanism independent of CYP2C19 metabolism. Similarly, we assess for any malabsorption that might impair antibiotic bioavailability — particularly in patients with H. pylori-induced atrophic gastritis that has damaged the absorptive epithelium.

We also counsel patients about strict adherence to the treatment regimen. H. pylori eradication requires completing the full course of antibiotics — missed doses or early cessation dramatically increases the risk of failure and resistance development. For patients at risk of poor adherence, we discuss once-daily regimens where possible and provide close follow-up to ensure completion.

Post-eradication follow-up is also critical. We recommend urea breath testing at least four weeks after completing treatment to confirm that eradication has been successful. We also assess the degree of gastric damage — particularly the presence of atrophic gastritis or intestinal metaplasia — which determines the intensity of surveillance needed going forward. Patients with extensive intestinal metaplasia or dysplasia may require endoscopic surveillance every one to three years to detect any progression toward malignancy.

Beyond conventional therapy, we are actively investigating gastric microbiome transplantation as a complementary approach for patients with refractory H. pylori. The premise is that the chronically inflamed and dysbiotic gastric microbiome that results from H. pylori infection creates an environment vulnerable to recolonisation. By transplanting a healthy gastric microbiome after successful eradication, we aim to establish colonisation resistance — an ecosystem so hostile to H. pylori that reinfection becomes unlikely. This is a frontier we are pioneering, with early results showing promise.

For patients who have experienced multiple treatment failures, the emotional toll is significant. The hope that accompanies each new regimen is followed by disappointment when that regimen also fails. This cycle erodes confidence in both the patient and the medical system. Our approach acknowledges this emotional reality — we move quickly to definitive diagnostics, use evidence-based regimens with high success rates, and provide close follow-up with clear communication about the rationale for each step in the treatment plan. For most patients with refractory H. pylori who follow this systematic approach, cure is achievable.

With the right approach — vonoprazan, rifabutin, amoxicillin, and bismuth — we achieve 92 percent eradication in patients who have failed everything else. Refractory H. pylori is a solvable problem.

If you have been struggling with H. pylori that will not clear, we encourage you to seek specialist evaluation. The tools to beat this infection exist — it is a matter of using them strategically.